LLY
Eli Lilly and Company
LLY has the edge over SGHT overall, supported by lower modeled downside and stronger fundamentals.
SGHT
Sight Sciences, Inc.
SGHT's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SGHT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SGHT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SGHT PE Valuation
SGHT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SGHT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SGHT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SGHT on earnings quality, reporting a profit while its opponent remains loss making.
SGHT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.51 | +$0.39 |
| Q2 2026 | -$0.55 | +$0.41 |
| Q1 2026 | -$0.70 | +$0.28 |
| Q4 2025 | -$0.74 | +$0.29 |
| Q3 2025 | -$0.90 | +$0.12 |
| Q2 2025 | -$0.96 | +$0.11 |
| Q1 2025 | -$0.98 | +$0.14 |
| Q4 2024 | -$1.03 | +$0.11 |
SGHT is still losing money, but far less than before: $0.51 per share over the past year, against $2.81 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SGHT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SGHT on profitability, with a higher operating margin.
SGHT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.9M | +25% |
| Q2 2026 | $23.4M | +20% |
| Q1 2026 | $19.7M | +13% |
| Q4 2025 | $20.4M | +6.9% |
| Q3 2025 | $19.9M | -1.2% |
| Q2 2025 | $19.6M | -8.5% |
| Q1 2025 | $17.5M | -9.1% |
| Q4 2024 | $19.1M | +1.7% |
SGHT's revenue has grown year over year for four quarters in a row: $25M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +15 points |
| Q2 2026 | -17% | +43 points |
| Q1 2026 | -63% | +16 points |
| Q4 2025 | -18% | +45 points |
| Q3 2025 | -40% | +16 points |
| Q2 2025 | -60% | -0.4 points |
| Q1 2025 | -79% | -2.7 points |
| Q4 2024 | -63% | -3.3 points |
SGHT's operating margin was −25% last quarter, up 15 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SGHT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SGHT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | +$6.4M |
| Q2 2026 | -$5.7M | +$2.1M |
| Q1 2026 | -$7.1M | +$4.5M |
| Q4 2025 | -$1.7M | +$1.9M |
| Q3 2025 | -$8.9M | -2958% |
| Q2 2025 | -$7.8M | +$1.8M |
| Q1 2025 | -$11.6M | -$1.7M |
| Q4 2024 | -$3.6M | +$3.2M |
SGHT has burned cash in almost every quarter: −$17M over the past year, against −$32M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SGHT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SGHT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +621K shares |
| 1 year | +5.2% | +2.7M shares |
| 3 years | +13% | +6.5M shares |
| 5 years | +474% | +45.5M shares |
| Available history | +57% | +20.1M shares |
SGHT has 55M diluted shares, up 5.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SGHT Net Leverage
SGHT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SGHT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.4 | Overbought |
| Stochastic | 91.0 | Overbought |
SGHT's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SGHT PE vs Healthcare Sector
SGHT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
SGHT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 19% above |
| 20 week MA | $7.85 | 40% above |
| 50 week MA | $6.42 | 71% above |
| 100 week MA | $5.07 | 117% above |
| 200 week MA | $5.73 | 92% above |
SGHT has climbed back above all five of its weekly moving averages, and it's now 92% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SGHT on returns for 2026, with the stronger performance.
SGHT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $32.7 | $18.5 | -43% |
| 2022 | $18.5 | $12.1 | -35% |
| 2023 | $12.1 | $5.16 | -57% |
| 2024 | $5.16 | $3.57 | -31% |
| 2025 | $3.57 | $8.82 | +147% |
| 2026 YTD | $8.82 | $11.0 | +25% |
SGHT's yearly returns have swung widely, from +147% in 2025 to −57% in 2023. It's up 25% so far in 2026.